Skip to content
Menu

IceCure Medical Ltd ICCM

Full chart Compare
Set alert

Price alert · ICCM

All alert types
0.80 USD -0.20 (-19.77%)

As ofNov 20, 2026, 12:38 PM EST

0.80 Day range 0.8561
0.65 52-week range 22.20
YTD
-95.63%
1 year
-95.89%

5D +0.3138 (+45.92%)

0.80001.0000FriTueWedThu0.9971
Market cap
4.45M
Revenue (ttm)
3.34M
EPS (ttm)
-6.84
Shares out
55.50M
Forward P/E
-4.48
YTD return
-95.63%
1-year return
-95.89%
50-day average
0.74766
Volume
115.64K
Avg volume
184.53K
Open
0.8498
Previous close
0.9971
Day's range
0.80 – 0.8561
52-week range
0.65 – 22.20
Beta
2.63
Price target
3.37 (+320.8%)

Key statistics

200-day average
0.852735
Enterprise value
28.55M
Price / sales
18.63
Price / book
4.21
Revenue growth
7.90%
Free cash flow
-6.62M
Total cash
10.46M
Total debt
520.00K
Return on equity
-94.22%
Short % of float
0.98%

Fundamental scorecard

8 of 25 checks passed on ICCM’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Financials — quick view

All financials
ICCM Revenue — quarterly 907.00K
ICCM Net income — quarterly -4.50M
ICCM EPS — quarterly -1.37

Earnings

ICCM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 26, 2024Sep 1, 2024-0.07-0.08-0.01-14.29%
Aug 20, 2024Jun 1, 2024-0.07———
Aug 20, 2024Jun 1, 2024-0.07-0.06+0.01+14.29%
May 28, 2024Mar 1, 2024-0.08———
May 28, 2024Mar 1, 2024-0.08-0.080.000.00%
Apr 3, 2024Dec 1, 20230.00-0.07——

Upgrades / downgrades

ICCM analyst upgrades and downgrades
DateFirmActionFromTo
Nov 27, 2024HC Wainwright & Co.reitBuyBuy
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Sep 12, 2024HC Wainwright & Co.reitBuyBuy
Aug 21, 2024HC Wainwright & Co.mainBuyBuy
Jul 2, 2024HC Wainwright & Co.reitBuyBuy
Jun 5, 2024HC Wainwright & Co.reitBuyBuy

About IceCure Medical Ltd

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Sector
Healthcare
Industry
Medical Devices
Country
Israel

News

Your note

Sign in to keep a note on ICCM — it syncs with the Stock Master app.